GLP-1 Drug Pioneers Propose Dropping GLP-1 as Obesity Target
Researchers behind the development of GLP-1 obesity drugs like Eli Lilly's Zepbound are advancing a new hypothesis: that targeting the GLP-1 hormone may not be necessary for effective weight loss. A team led by Richard DiMarchi and Matthias Tschöp has created an experimental drug activating GIP and glucagon hormone receptors, with rodent and monkey studies suggesting weight loss comparable to existing therapies at sufficient doses.
Advertisement: Article Inline